PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review

Immune checkpoint inhibitors(ICIs), including cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1) inhibitors, have been shown to have antitumor activity in various solid tumors. Their mechanism of action is to selectively restore and normalize...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Na, Liu, Xiangliang, Ye, Xiaojun, Song, Wei, Lu, Jin, Chen, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478917/
https://www.ncbi.nlm.nih.gov/pubmed/36119464
http://dx.doi.org/10.3389/fonc.2022.961266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478917/
https://www.ncbi.nlm.nih.gov/pubmed/36119464
http://dx.doi.org/10.3389/fonc.2022.961266

Ejemplares similares